On September 13, 2021, Plus Therapeutics, Inc. announced the appointment of Dr. Norman LaFrance as Chief Medical Officer and Senior Vice President of the Company, effective on or around December 8, 2021. Dr. LaFrance, age 74, will be responsible for leading and developing clinical development strategy and hands-on leadership of trials across all phases of development; he will lead the regulatory process with the U.S. Food & Drug Administration (“FDA”) and other global agencies from investigational new drug application (IND) through new drug application (NDA) (or biologics license application (BLA)); and he will lead and build the Company’s clinical development medical affairs and clinical operations teams. Prior to joining the Company, Dr. LaFrance served as Chief Medical Officer and Senior Vice President at Jubilant Pharma Ltd. for over nine years where he was responsible for all Pharma Medical & Regulatory Affairs activities. Dr. LaFrance has spent four decades in the pharmaceutical and healthcare industry, academia and medical practice. His background includes strategic planning and management of pharmaceutical development for approval by the FDA as well as clinical and academic experience. In addition, Dr. LaFrance practiced medicine for 10 years and held academic faculty appointments at Johns Hopkins University School of Medicine in the Departments of Medicine and Radiology and the Department of Radiological Sciences in the Johns Hopkins School of Hygiene and Public Health. He is double board certified in internal medicine and nuclear medicine. He is a graduate of the medical school at the University of Arizona and received his bachelor of science and master of engineering degrees in nuclear engineering and science from Rensselaer Polytechnic Institute. On September 7, 2021, in connection with Dr. LaFrance’s appointment as CMO for the Company, the Company entered into an Employment Agreement (the “LaFrance Employment Agreement”) with Dr. LaFrance, effective December 8, 2021. Pursuant to the terms of the LaFrance Employment Agreement, Dr. LaFrance will receive an initial annual base salary of $440,000 and will be eligible to participate in the Company’s benefit and compensation plans. Dr. LaFrance has been assigned an initial annual target bonus of 35% of his base salary. Further, in an effort to induce Dr. LaFrance to accept the offer, Dr. LaFrance will also receive options to purchase up to 120,000 shares of common stock of the Company, which will have an exercise price per share equal to the fair market value of the common stock on the date of grant and which are expected to vest and become exercisable in monthly installments over the next four years, subject to a one-year cliff. In addition, it is expected that Dr. LaFrance will enter into the Company’s standard form of indemnification agreement.